fulvestrant injection
astrazeneca pharmaceuticals lp - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data] . advise pregnant women of the potential r
fulvestrant injection
hbt labs, inc. - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant injection is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have
fulvestrant injection
chia tai tianqing pharmaceutical group co., ltd. - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant injection is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have
fulvestrant injection, solution
dr.reddy's laboratories inc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant is indicated for the treatment of : - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in associatio
fulvestrant injection
hikma pharmaceuticals usa inc. - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant injection is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been repo
fulvestrant injection
alembic pharmaceuticals inc. - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant injection is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema
fulvestrant injection
sandoz inc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2) ]. risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data ]. advise pregnant women of the potential
fulvestrant injection
glenmark pharmaceuticals inc., usa - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2)]. risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1 )]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data] . advise pregnant women of the potential risk to a fetus. the estimated background risk of major b
fulvestrant injection
meitheal pharmaceuticals inc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: - hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or - hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. combination therapy fulvestrant injection is indicated for the treatment of: - hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactio
fulvestrant injection
northstar rxllc - fulvestrant (unii: 22x328qoc4) (fulvestrant - unii:22x328qoc4) - monotherapy fulvestrant injection is indicated for the treatment of: combination therapy fulvestrant injection is indicated for the treatment of: fulvestrant is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. hypersensitivity reactions, including urticaria and angioedema, have been reported in association with fulvestrant [see adverse reactions (6.2) ]. risk summary based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicity, including skeletal malformations and fetal loss, at daily doses that were 6% and 30% of the maximum recommended human dose based on mg/m2 , respectively [see data ]. advise pregnant women of the potential